Heveny myeloid leukaemiás betegeink kezelésével szerzett tapasztalataink (2007-2013)

Translated title of the contribution: Heveny myeloid leukaemiás betegeink kezelésével szerzett tapasztalataink (2007-2013)

Anna Selmeczi, Miklós Udvardy, Árpád Illés, Béla Telek, Attila Kiss, Péter Batár, Gyula Reményi, Róbert Szász, Zsófia Ujj, Adrienn Márton, Anikó Újfalusi, Zsuzsanna Hevessy, László Pinczés, Judit Bedekovics, László Rejto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Mortality of acute myeloid leukemia is still 60-70% in young (<60 years) adults and 90% in elderly (≥60 years) patients. Aim: The aim of the authors was to analyse the outcome of treatment in their patients with acute myeloid leukemia. Method: From 2007 to 2013, 173 patients with acute myeloid leukemia were treated. Patients were classified according to the European LeukemiaNet prognostic guideline. Association between mortality and the type of acute myeloid leukemia (secundary or primary), dose of daunoblastin at induction of treatment, and the rate of minimal residual disease were investigated. Results: The 5-year survival probability was 25% in young adults and 2% in the elderly. The survival was significantly influenced by these prognostic factors. The 5-year survival rate was 50% in the young, favorable prognostic group. The 90 mg/m2 daunoblastin dose was found to be beneficial. Addition of bortezomib to the standard induction protocol had an additional beneficial effect. Conclusions: The speed and depth of the response to induction therapy, and the initial white blood cell count had an apparent effect on survival.

Translated title of the contributionHeveny myeloid leukaemiás betegeink kezelésével szerzett tapasztalataink (2007-2013)
Original languageHungarian
Pages (from-to)653-658
Number of pages6
JournalOrvosi hetilap
Volume155
Issue number17
DOIs
Publication statusPublished - Apr 1 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Heveny myeloid leukaemiás betegeink kezelésével szerzett tapasztalataink (2007-2013)'. Together they form a unique fingerprint.

  • Cite this

    Selmeczi, A., Udvardy, M., Illés, Á., Telek, B., Kiss, A., Batár, P., Reményi, G., Szász, R., Ujj, Z., Márton, A., Újfalusi, A., Hevessy, Z., Pinczés, L., Bedekovics, J., & Rejto, L. (2014). Heveny myeloid leukaemiás betegeink kezelésével szerzett tapasztalataink (2007-2013). Orvosi hetilap, 155(17), 653-658. https://doi.org/10.1556/OH.2014.29884